SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer
Authors
Keywords
-
Journal
JCI Insight
Volume 6, Issue 18, Pages -
Publisher
American Society for Clinical Investigation
Online
2021-09-22
DOI
10.1172/jci.insight.146098
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- SLFN11 expression in advanced prostate cancer and response to platinum-based chemotherapy
- (2020) Vincenza Conteduca et al. MOLECULAR CANCER THERAPEUTICS
- BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers
- (2020) Florence Coussy et al. Science Translational Medicine
- Tumour immune cell infiltration and survival after platinum-based chemotherapy in high-grade serous ovarian cancer subtypes: A gene expression-based computational study
- (2020) Rong Liu et al. EBioMedicine
- Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells
- (2020) Rebecca L. Lloyd et al. ONCOGENE
- Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy
- (2020) Maud Mayoux et al. Science Translational Medicine
- Immunohistochemical analysis of SLFN11 expression uncovers potential non-responders to DNA-damaging agents overlooked by tissue RNA-seq
- (2020) Tsuyoshi Takashima et al. VIRCHOWS ARCHIV
- Chromatin Remodeling and Immediate Early Gene Activation by SLFN11 in Response to Replication Stress
- (2020) Junko Murai et al. Cell Reports
- Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response
- (2020) Jessica Roelands et al. Journal for ImmunoTherapy of Cancer
- SLFN11 can sensitize tumor cells towards IFN-γ-mediated T cell killing
- (2019) Riccardo Mezzadra et al. PLoS One
- Epithelial ovarian cancer
- (2019) Stephanie Lheureux et al. LANCET
- High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints
- (2019) Michael-Antony Lisio et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Differential uptake, kinetics and mechanisms of intracellular trafficking of next-generation antisense oligonucleotides across human cancer cell lines
- (2019) Emily Linnane et al. NUCLEIC ACIDS RESEARCH
- Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
- (2019) Davide Bedognetti et al. Journal for ImmunoTherapy of Cancer
- Schlafen11 Expression Is Associated With the Antitumor Activity of Trabectedin in Human Sarcoma Cell Lines
- (2019) JUNYA IWASAKI et al. ANTICANCER RESEARCH
- Correction to: Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer
- (2019) Edoardo Isnaldi et al. BREAST CANCER RESEARCH AND TREATMENT
- Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod
- (2019) Mariya Rozenblit et al. Scientific Reports
- Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy
- (2019) Kevin Shee et al. PLoS One
- The Immune Landscape of Cancer
- (2018) Vésteinn Thorsson et al. IMMUNITY
- Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
- (2018) M. Catherine Pietanza et al. JOURNAL OF CLINICAL ONCOLOGY
- The ATR Inhibitor AZD6738 Synergizes with GemcitabineIn VitroandIn Vivoto Induce Pancreatic Ductal Adenocarcinoma Regression
- (2018) Yann Wallez et al. MOLECULAR CANCER THERAPEUTICS
- SLFN11 Blocks Stressed Replication Forks Independently of ATR
- (2018) Junko Murai et al. MOLECULAR CELL
- Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion
- (2018) Flávia Castro et al. Frontiers in Immunology
- Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer
- (2018) Mandy Stanske et al. NEOPLASIA
- Cancer of the ovary, fallopian tube, and peritoneum
- (2018) Jonathan S. Berek et al. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
- DNA damage-induced cell death relies on SLFN11-dependent cleavage of distinct type II tRNAs
- (2018) Manqing Li et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Cisplatin-induced immune modulation in ovarian cancer mouse models with distinct inflammation profiles
- (2018) Shannon Grabosch et al. ONCOGENE
- Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy
- (2018) Razvan Cristescu et al. SCIENCE
- WikiPathways: a multifaceted pathway database bridging metabolomics to other omics research
- (2017) Denise N Slenter et al. NUCLEIC ACIDS RESEARCH
- Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer
- (2017) C. Allison Stewart et al. Oncotarget
- The prognostic value of tumor-infiltrating T lymphocytes in ovarian cancer
- (2017) Jun Li et al. Oncotarget
- Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis
- (2017) Wouter Hendrickx et al. OncoImmunology
- Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer
- (2017) et al. JAMA Oncology
- PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer
- (2016) Benjamin H. Lok et al. CLINICAL CANCER RESEARCH
- Disentangling the relationship between tumor genetic programs and immune responsiveness
- (2016) Davide Bedognetti et al. CURRENT OPINION IN IMMUNOLOGY
- Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
- (2016) Junko Murai et al. Oncotarget
- A Multi-Method Approach for Proteomic Network Inference in 11 Human Cancers
- (2016) Yasin Şenbabaoğlu et al. PLoS Computational Biology
- High SLFN11 expression predicts better survival for patients with KRAS exon 2 wild type colorectal cancer after treated with adjuvant oxaliplatin-based treatment
- (2015) Yanhong Deng et al. BMC CANCER
- RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
- (2015) S. Loi et al. CLINICAL CANCER RESEARCH
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
- (2015) Stefani Spranger et al. NATURE
- Robust enumeration of cell subsets from tissue expression profiles
- (2015) Aaron M Newman et al. NATURE METHODS
- limma powers differential expression analyses for RNA-sequencing and microarray studies
- (2015) Matthew E. Ritchie et al. NUCLEIC ACIDS RESEARCH
- Immunological metagene signatures derived from immunogenic cancer cell death associate with improved survival of patients with lung, breast or ovarian malignancies: A large-scale meta-analysis
- (2015) Abhishek D. Garg et al. OncoImmunology
- The Molecular Signatures Database Hallmark Gene Set Collection
- (2015) Arthur Liberzon et al. Cell Systems
- Copy Number Loss of the Interferon Gene Cluster in Melanomas Is Linked to Reduced T Cell Infiltrate and Poor Patient Prognosis
- (2014) Peter S. Linsley et al. PLoS One
- CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2
- (2013) D Bedognetti et al. BRITISH JOURNAL OF CANCER
- The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures
- (2013) Jérôme Galon et al. IMMUNITY
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Prediction of Response to Anticancer Immunotherapy Using Gene Signatures
- (2013) Ena Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Structure of the full-length HCV IRES in solution
- (2013) Julien Pérard et al. Nature Communications
- Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11
- (2012) Manqing Li et al. NATURE
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
- (2012) Guangchuang Yu et al. OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY
- Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents
- (2012) G. Zoppoli et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis
- (2011) Wei-Ting Hwang et al. GYNECOLOGIC ONCOLOGY
- Clinical Trials in Recurrent Ovarian Cancer
- (2011) Michael Friedlander et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Frozen robust multiarray analysis (fRMA)
- (2010) M. N. McCall et al. BIOSTATISTICS
- Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules
- (2010) Andrew E Teschendorff et al. BMC CANCER
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started